HPRA Strategic Plan 2026–2029

πŸ“„

HPRA Strategic Plan 2026–2029

Publisher: Health Products Regulatory Authority (HPRA), Ireland
Document type: Strategic plan
Publication date: 24 September 2026
Status: Published β€” Strategic Plan 2026–2029
Format: PDF, 17 pages (English)

Summary

The Health Products Regulatory Authority (HPRA), Ireland’s national regulator for health products, has published its Strategic Plan 2026–2029. The document sets out the authority’s priorities for the four-year period as it responds to scientific advances, changing European and national legislation, and pressures affecting global health product supply chains.

The plan is structured around four strategic goals: regulating for the future; digital first, data driven; partnerships, trust and transparency; and people, capability and culture. Under the first goal, the HPRA intends to support innovation through adaptive regulatory approaches, contribute to emerging legislation and policy, strengthen its participation in the European regulatory network, and improve systems for monitoring and managing the availability of health products.

Digital transformation is a central priority. The HPRA plans to modernise regulatory systems through automation, improved connectivity and data exchange aligned with EU digital standards. It also intends to strengthen data governance and integrate real-world and other novel data sources into regulatory processes. The strategy identifies artificial intelligence and advanced data analytics as areas for further exploration in business and regulatory activities, alongside contributions to standards and guidance on AI in health product regulation.

The remaining goals focus on public trust, patient-centred regulation, cooperation with national, EU and international regulatory bodies, and the organisational capabilities needed to deliver the HPRA’s remit. Planned measures include further engagement through the HPRA Patient Forum, stronger integration with the health system, workforce development, succession planning and long-term financial, environmental and infrastructure sustainability. The strategy is a statement of the authority’s priorities for 2026–2029; it does not itself introduce new regulatory requirements for industry.

Intended audience

Regulatory affairs professionals, pharmaceutical and veterinary medicinal product manufacturers, marketing authorisation holders, medical device stakeholders, healthcare and life sciences organisations, and other parties monitoring the development of Ireland’s regulatory system and its contribution to the European regulatory network.

POPULAR DOCUMENTS